Announcement PDF ASX: RAD | NASDAQ: RADX July 2026 A Multi-Asset Radiopharmaceutical Platform Capital Raising Presentation Clinical-stage oncology radiopharmaceuticals — diagnostics and therapeutics 1 Notice & Disclaimer 2 The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Radiopharm Theranostics Ltd ACN 647 877 889 (Company). In preparing this presentation, the Company did not take into account the investment objectives, financial situation and particular needs of any particular investor. Further advice should be obtained from a professional investment adviser before taking any action on any information dealt with in the presentation. Those acting upon any information without advice do so entirely at their own risk. Whilst this presentation is based on information from sources which are considered reliable, no representation or warranty, express or implied, is made or given by or on behalf of the Company, any of its directors, or any other person about the accuracy, completeness or fairness of the information or opinions contained in this presentation. No responsibility or liability is accepted by any of them for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this presentation. Neither the Company nor any of its directors, officers, employees, advisers, associated persons or subsidiaries are liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon any statement in this presentation or any document supplied with this presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed. Certain statements contained in this presentation, including, without limitation, statements containing the words “believes,” “plans,” “expects,” “anticipates,” and words of similar import, constitute “forward- looking statements.” Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following: the risk that our clinical trials will be delayed and not completed on a timely basis; the risk that the results from the clinical trials are not as favourable as we anticipate; the risk that our clinical trials will be more costly than anticipated; and the risk that applicable regulatory authorities may ask for additional data, information or studies to be completed or provided prior to their approval of our products. Given these uncertainties, undue reliance should not be placed on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements contained herein to reflect future events or developments except as required by law. This presentation is not a prospectus or other disclosure document under the Corporations Act 2001 (Cth) and will not be lodged with the Australian Securities and Investments Commission. This presentation is for information purposes only and is not an invitation or offer of securities for subscription, purchase or sale in any jurisdiction. The distribution of this presentation (including electronically) outside Australia is restricted by law. If you come into possession of this presentation, you should observe such restrictions as any non- compliance with these restrictions could contravene applicable securities laws (see the section captioned ‘International offer restrictions’). In particular, this document does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States. The New Shares, Attaching Options and shares underlying the Attaching Options have not been, and will not be, registered under the US Securities Act of 1933 and may not be offered or sold in the United States except in transactions registered under the US Securities Act or in transactions exempt from, or not subject to, the registration requirements of the US Securities Act and applicable US state securities laws. Any opinions expressed reflect the Company’s position at the date of this presentation and are subject to change. INVESTMENT HIGHLIGHTS A multi-asset radiopharmaceutical platform — a Phase III-ready imaging lead plus four clinical-stage therapeutics. Clear path to Phase III FDA Fast Track; registrational Phase III ready to start Q4 2026. RAD101 large unmet market ~300,000 US patients p.a.; potential >US$500m US sales; no direct competitor. Established partners Siemens Healthineers for Ph 3 distribution in USA; Advanced Strategic discussions for partnering; M&A company retained Phase I: Efficacy at Dose Level 3 First patient treated at 90mCi achieved -43% tumor reduction; Second patient treated shows a similar positive trend Funded through key milestones Pro-forma cash of A$28.5m1 (3 July 2026) post raise RAD101 HIGHLIGHTS: POSITIVE PHASE 2b READOUT: ≥ 93% of the patients achieved the Primary Endpoint RAD204 HIGHLIGHTS: CLINICAL EFFICACY, 1st patient dosed at 90 mCi reported sustained tumor reduction RAD 204 very large market First in class; no direct competitor ~USD10B total addressable market 3 1A$12.5 million Placement and fully subscribed A$6.0 million SPP Company Pipeline in Clinical Stage First two programs reporting strong clinical data. Additional upside from the other three Phase I trials PROGRAM INDICATION ISOTOPE PHASE I PHASE II PHASE III CATALYSTS PD-L1+ solid tumors 177Lu Clinical activity reported July 2026 Dose-escalation completion Q4 2026 – Q1 2027 HER2+ solid tumors 177Lu Dose-escalation completion H1 2027 RAD402 KLK3 (prostate cancer) 161Tb Dose-escalation completion H2 2027 RV01 B7-H3 (solid tumors) 177Lu Dose-escalation completion H2 2027 RAD101 Imaging — brain mets 18F Positive Phase 2b read-out July 2026 ¹⁷⁷Lu, lutetium-177; ¹⁶¹Tb, terbium-161; ¹⁸F, fluorine-18; B7-H3, B7 homolog 3; HER2, human epidermal growth factor receptor 2; KLK3, kallikrein-3; PD-L1, programmed death ligand-1. RAD202 RAD204 4 One Phase IIb imaging lead (RAD101) and four Phase I therapeutics across validated oncology targets. Pharma Partnership Window KEY CATALYSTS & MILESTONES Consistent clinical & regulatory delivery since mid-2025, with multiple value-driving catalysts approaching from mid-2026 into 2027 Achieved milestones sourced from Radiopharm Theranostics ASX and GlobeNewswire announcements (Jul 2025 - Apr 2026); upcoming timing reflects management expectations and is indicative. Phase IIb topline readout (Jul 2026) not yet reported. Achieved Milestones Upcoming Milestones RAD101 Phase IIb 1st interim: 92% MRI concordance (11/12) Dec 2025 RV-01 first patients dosed (Phase 1/2a) Feb 2026 RAD101 Phase IIb 2nd interim: 90% MRI concordance (18/20) Mar 2026 Siemens Healthineers supply pact for planned US Phase III Apr 2026 RAD101 Phase IIb readout (final 30- patient cohort) Jul 2026 FDA Phase III protocol alignment meeting Sep 2026 RAD101 Phase III registrational trial starts Q4 2026 Partnering / monetisation discussions advance Q4 2026 1H 2027 RAD204 Efficacy data released RAD402 first patients dosed (Phase 1/2a) Mar 2026 RAD204 Phase I read out RAD202 Phase I read out RAD202 Expected Efficacy data released Q4 2026 5 6 RAD 101 DIAGNOSTIC Imaging lead asset — RAD 101 First-in-class PET imaging agent for brain metastases T H E A G E N T FASN Tumor target Pivalate Targeting molecule ¹⁸F PET isotope Short-chain fatty-acid analogue Brain-metastasis indication Fatty acid synthase (FASN) — a validated target Targets the FASN fatty-acid metabolism pathway Detects recurrence after stereotactic radiosurgery (SRS) Addresses a major diagnostic gap in neuro-oncology High unmet need in early relapse detection FDA Fast Track Phase 2b Positive Read-out First-in-class PET imaging for post-SRS brain-metastasis recurrence — no direct competitor. FASN, fatty acid synthase; ¹⁸F, fluorine-18; PET, positron emission tomography; SRS, stereotactic radiosurgery. RAD 101 DIAGNOSTIC Imaging lead asset — RAD101 First-in-class PET tracer to advance to Phase 3 — near-term value and optionality THE NEED High unmet Need - SoC MRI falls short Early identification of recurrent brain metastases is urgent need in suspected relapse after SRS. THE MARKET 300,000 ~300,000 new brain-metastasis patients post-SRS each year (US) — with no direct competitor in this imaging sector. THE ASSET First-in-class PET tracer RAD101 (¹⁸F-pivalate) is a FASN-targeted PET tracer designed to close this diagnostic gap. THE DATA Phase 3 preparation started Company-sponsored Phase 2b (US, N=30); interim N=20 positive · Positive Phase IIb data Islam S, et al. EJNMMI 2025. doi.org/10.1007/s00259-025-07118-0. FASN, fatty acid synthase; MRI, magnetic resonance imaging; PET, positron emission tomography; SoC, standard of care; SRS, stereotactic radiosurgery; SUV, standardized uptake value. 7 RAD 101 DIAGNOSTIC RAD101 Phase IIb — primary endpoint readout Primary endpoint met — high concordance with MRI. PRIMARY ENDPOINT Concordance with MRI SUCCESSFULLY ACHIEVED ≥ 93% 28* / 30 patients concordant SECONDARY ENDPOINT · INTERIM ANALYSIS SPECIFICITY PENDING Not yet available Read-out expected Q4 2026 Primary endpoint met — ≥ 93% concordance with MRI · full sensitivity and specificity read-out expected Q4 2026. MRI, magnetic resonance imaging. 8 SENSITIVITY INTERIM ≥ 86% 12 / 14 patients *3/30 Patient data not yet available RAD 101 DIAGNOSTIC RAD101 - Next steps to Phase 3 A clear, de-risked path to a Phase 3 start in Q4 2026 MILESTONES May 2026 Advisory Board Supportive of Phase 3 Sep 2026 FDA protocol meeting Align on trial design Q4 2026 Phase 3 start Ready to initiate Trial design N=150–200 patients · primary endpoints: sensitivity & specificity Supply & logistics US radiolabeling & distribution outsourced to a global leader — contract signed with Siemens PETNET Partnering opportunity assessment — contract signed with a radiopharma specialist in M&A 9 Partnering opportunity assessment 10 RAD 101 DIAGNOSTIC Structured partnering process underway with global radiopharma players. Radiopharmaceuticals are an actively consolidating sector - over US$10bn of M&A and partnerships in recent years - as Radiopharm advances a de-risked, multi-asset pipeline toward partnering. Potential Partners Global radiopharma-active pharma — illustrative universe Process Status – Specialist radiopharmaceutical M&A adviser engaged – Initial meetings conducted; parties assessing the opportunity – Further partner interactions underway Recent Radiopharmaceutical Deals Selected M&A and partnerships, 2017–2025 Bristol Myers Squibb / RayzeBio US$4.1bn · 2023 Novartis / Adv. Accelerator Apps US$3.9bn · 2017 Novartis / PeptiDream up to US$2.7bn · 2025 AstraZeneca / Fusion Pharma US$2.4bn · 2024 Novartis / Mariana Oncology up to US$1.75bn · 2024 Eli Lilly / Point Biopharma US$1.4bn · 2023 Eli Lilly / Aktis Oncology up to US$1.1bn · 2024 AstraZeneca / Nucleus RadioPharma Investment · 2025 POTENTIAL FIRST-IN-CLASS DIAGNOSTIC WITH COMMERCIAL SCALE ~300,000 patients/year (US), Potential >$500M annual sales (US) 11 RAD 101 DIAGNOSTIC Year 1 Year 2 Year 3 Year 4 Year 5 Year 6 Year 7 Year 8 Potential first-in-class diagnostic with scalable adoption Clear pathway to monetization through partnering or commercialization Comparables: PYLARIFY (Lantheus) 12-month sales in US: ~970m Illuccix (Telix) 12-month sales in US: ~700m ~300,000 US patients p.a.; >US$500m US sales potential vs Pylarify (~$970m) and Illucix (~$700m). 12 RAD 101 DIAGNOSTIC Why RAD101 will be adopted Four reasons RAD101 fits — and wins — in post-treatment neuro-oncology imaging. THE NEED Clear unmet need MRI is frequently equivocal in post-treatment brain metastases. THE FIT Fits existing workflow PET is already standard — no new infrastructure required. THE MOMENT High-value decision point Resolves the critical post-SRS recurrence question. THE WHITE SPACE No direct competitor First-in-class PET agent for this indication. Clear unmet need · fits existing PET workflow · high-value decision point · no direct competitor. MRI, magnetic resonance imaging; PET, positron emission tomography; SRS, stereotactic radiosurgery. RAD 204 THERAPEUTIC RAD204 — First-in-class PD-L1 targeted radiotherapy Validated immuno-oncology target First-in-class PD-L1 targeted 177Lu radiotherapy POTENTIAL POSITIONING LEAD INDICATION Post-IO NSCLC High unmet-need setting after immunotherapy EXPANSION Multiple solid tumors Across PD-L1–expressing tumor types Expands a proven IO target into a new therapeutic modality IO, immuno-oncology; NSCLC, non-small cell lung cancer; PD-L1, programmed death ligand-1; 177Lu, lutetium-177. 13 RAD 204 THERAPEUTIC RAD204: early efficacy signal First patient dosed at Cohort 3 (90 mCi) — dose escalation ongoing under a Bayesian (BOIN) design TRIAL DESIGN PRIMARY OBJECTIVES • Safety & tolerability of ¹⁷⁷Lu-RAD204 • Recommended Phase 2 dose STUDY DESIGN • BOIN dose-finding design • Population: prior PD-L1+ (>1%) metastatic disease Phase I — Treatment (dose escalation) 30 mCi 1.1 GBq DL1 Completed · 3 pts 60 mCi 2.2 GBq DL2 Completed · 3 pts 90 mCi 3.3 GBq DL3 2/3 recruited 120 mCi (tbd) 4.4 GBq DL4 Planned DL1–DL2: Tumor uptake confirmed; favorable safety profile, no DLT. DL3: Early clinical signal (see next slide). BOIN, Bayesian optimal interval; DL, dose level; GBq, gigabecquerel; mCi, millicurie; PD-L1, programmed death ligand-1; tbd, to be determined. 14 RAD 204 THERAPEUTIC RAD204: early clinical activity First patient at 90 mCi achieved a confirmed RECIST Partial Response with durable (7+ months) tumor shrinkage Partial Response RECIST Confirmed (Pt #7) 7+ months PFS No evidence of progression DOSE LEVEL #3 · 90 mCi (3.3 GBq) · NSCLC Patient #7 NSCLC · No DLT PARTIAL RESPONSE Safety No DLT Kidney dose* 8.1 Gy (cumulative, 4 doses) PFS 7+ months, no progression Completed 4 doses. Tumor shrinkage by cycle (dose) -19% D1 -43% D2 -43% D3 -35% D4 *FDA guidance = 23 Gy (under discussion). 15 Patient #8 NSCLC · No DLT STABLE DISEASE Safety No DLT Kidney dose* 0.9 Gy (Dose 1) PFS 2+ months, no progression Only 1 dose received, continuing to next dose Tumor shrinkage by cycle (dose) -7% D1 2+ months PFS No evidence of progression Stable disease Positive trend in tumor reduction (Pt #8) RAD 204 THERAPEUTIC Baseline October ‘25 1st dose November ‘25 2nd dose January ‘26 3rd dose March ‘26 Patient #7 — first patient treated at 90 mCi Durable confirmed RECIST partial response across multiple cycles NSCLC — progressed after multiple prior therapies • External-beam radiotherapy • Chemotherapy (carboplatin, taxane) • PD-L1 checkpoint inhibitor Expected PFS 4–6 months Treated with RAD204 at 90 mCi Confirmed RECIST PR 43% tumor-size reduction PFS 7 months & ongoing SPECT/CT — Complete Response RLL primary at IM, C1–C3 SUVmax 2.71 → 1.14 → 0.93 → 0 / nd CORONAL CT · RLL PRIMARY 16 RAD204 Investment Case RAD 204 THERAPEUTIC PD-L1 is the largest and most validated immuno-oncology target Targeted radiotherapy introduces a new principle combining two synergistic mechanisms of action Addressable market (US, post-IO NSCLC) 40,000–65,000 patients per year Platform enables continued optimization across the pipeline  Early clinical signal already observed at dose level #3  First-in-class: no radiopharma competitors identified 17 RAD 202 THERAPEUTIC Phase I dose escalation with a favorable safety profile First two cohorts completed with no DLTs — Dose Level 3 dosed at 130 mCi TRIAL DESIGN PRIMARY OBJECTIVES (PHASE 1) • Safety & tolerability of ¹⁷⁷Lu-RAD202 • Recommended Phase 2 dose POPULATION • HER2+ (IHC, ISH) advanced or metastatic solid tumors Phase I — Treatment (dose escalation) 30 mCi 1.1 GBq DL1 Completed · 3 pts 75 mCi 2.7 GBq DL2 Completed · 3 pts 130 mCi 4.8 GBq DL3 Cohort 3 dosed 3/3 recruited 200 mCi (tbd) 7.4 GBq DL4 Planned DL1–DL2: Tumor uptake confirmed; favorable safety, no DLT. DL3: Clinical activity under assessment. a/m, advanced or metastatic; DL, dose level; DLT, dose-limiting toxicity; GBq, gigabecquerel; HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; ISH, in situ hybridization; mCi, millicurie; TBD, to be determined. 18 RAD 202 THERAPEUTIC RAD202: Cohort #3 expected to complete by September Evidence of tumor radiation at Dose Level 3 (130 mCi) Completing by September 3 patients dosed in Cohort #3 No DLT to date Safety assessment ongoing Next dose: 200 mCi Escalation planned DOSE LEVEL 3 · 130 mCi (4.8 GBq) #8 Patient #8 Colorectal PD Safety No DLT Kidney (at risk) 10 Gy · avg 2 doses Tumor uptake 2.4 Gy · avg 2 doses RECIST — Stable disease 3 mo (dose 1+2); progressive disease before 3rd dose. #9 Patient #9 Breast ONGOING, SD Safety Assessment ongoing Kidney (at risk) 11 Gy · 1 dose Tumor uptake 9.8 Gy · 1 dose RECIST Stable Disease Unchanged after 1st dose; continuing to Dose 2 (Jul 14). #10 Patient #10 Breast ONGOING Safety Assessment ongoing Kidney (at risk) 8.9 Gy* Tumor uptake 15 Gy* RECIST — Continuing to Dose 2 (Aug 4). High uptake of the drug in the patients DLT, dose-limiting toxicity; Gy, gray; mCi, millicurie; RECIST, Response Evaluation Criteria in Solid Tumours * Preliminary values, calculated from normalized imaging dose. 19 ! SUMMARY A multi-asset radiopharmaceutical platform — a Phase III-ready imaging lead plus four clinical-stage therapeutics. RAD 101 Successful Phase 2b trial in Brain Mets Advancing to single registrational Phase 3 No Competition Attractive asset for M&A PIPELINE UPSIDE RAD 202 has very promising tumor uptake RAD 402 & RV01 trials are enrolling fast, with read-out in 2027 No dose-limiting toxicities reported RAD 204 Strong signal of Clinical Efficacy reported in Phase I, Dose Level 3 No dose-limiting toxicity reported No Competitor identified Very Large total addressable market 2026 CATALYSTS 2027 CATALYSTS 20 BOARD & MANAGEMENT Leadership with hands-on, successful development and commercial track record Direct blockbuster radiopharmaceutical pedigree: Novartis / AAA (Lutathera, Lu-PSMA-617), Siemens PETNET and ANSTO — operators who have built and commercialised the assets that define the sector. 21 Riccardo Canevari Chief Executive Officer • Radiopharm Theranostics CEO since September 2021 • Previously, Chief Commercial Officer of Novartis Company Advanced Accelerator Applications S.A. • Lead for Lutathera in-market growth strategy & Pluvicto launch strategy • Senior Vice President & Global Head, Breast Cancer Franchise, for Novartis Oncology since 2017 • Founder of Radiopharm Theranostics • 25 years experience as a life sciences entrepreneur • Founder, Chairman, non-executive director or CEO of more than fifteen companies in the US, Australia and Asia • Previous and current Boards include Imugene, Chimeric Therapeutics, Viralytics, Prescient Therapeutics, Polynoma and Arovella Therapeutics Paul Hopper Executive Chairman Dr. Dimitris Voliotis Chief Medical Officer • Over 20 years experience in pharmaceutical and biotechnology sectors across US and Europe, with an emphasis on radiopharmaceuticals • Dr Voliotis has designed and executed multiple registrational trials in numerous oncology indications, multiple INDs, preclinical through to first in human trials and has overseen numerous regulatory submissions • Previously, Senior Vice President, Head of Clinical Development at Convergent Therapeutics Dr. Ken Herrmann Scientific Advisory Board • Over 18 years of experience in radioligand therapy and early clinical translation of novel radioligand therapy concepts • Dr Herrmann currently serves as Chair of the Department of Nuclear Medicine at Universitätsmedizin Essen, Germany • Experienced across translating theranostics, ranging from first in human use to contributing to pivotal regulatory approval receiving phase 3 studies Dr. Oliver Sartor Scientific Advisory Board • Dr Sartor is an internationally recognised medical oncologist and scientist specialising in prostate cancer and radiopharmaceutical therapies • Currently serves as Director of Radiopharmaceutical Clinical Trials and Chair of the Genitourinary Cancer Disease Group at the world-renowned Mayo Clinic, in Rochester, Minnesota. • Since 1990, he has focused on prostate cancer clinical research, authoring more than 500 peer-reviewed publications and leading multiple pivotal Phase 3 trials that resulted in FDA approvals. LEADERSHIP TEAM SCIENTIFIC ADVISORY BOARD CAPITAL RAISING Offer details · Use of funds · Indicative timetable 22 CAPITAL RAISING OVERVIEW The Company is raising ~A$18.5 million1 via a Placement, US Direct Registration Offering & SPP • A two-tranche Placement of fully paid ordinary shares (“New Shares”) to sophisticated and professional investors of ~A$6.7m (before costs)(“Placement”) comprising of: o Tranche 1 Placement to raise ~A$6.1 million (before costs) through the issuance of ~408.8 million New Shares utilising the Company’s available placement capacity under ASX Listing Rule 7.1 and 7.1A (“Tranche 1 Placement”); and o Tranche 2 Placement to raise ~A$0.6 million (before costs) through the issuance of ~40.0 million New Shares, subject to shareholder approval at an Extraordinary General Meeting (“EGM”) to be held on or around Friday, 11 September 2026 (“Tranche 2 Placement”). Placement • A current direct SEC-registered offering in the United States to raise ~US$4.1 million (~A$5.8 million) through the issuance of ~1.3 million American Depositary Shares (“ADS”) representing ~384.5 million fully paid ordinary shares at US$3.16 per ADS (“US Direct Registration Offering”). US Direct Registration Offering • A Share Purchase Plan to eligible shareholders raising approximately A$6.0 million2 (“SPP”). Eligible shareholders will be entitled to subscribe for up to A$100,000 of fully paid ordinary shares. The issue of shares under the SPP is subject to shareholder approval at an Extraordinary General Meeting (“EGM”) to be held on or around Friday, 11 September 2026. o The company has received commitments from investor to subscribe for up to A$3.0m in SPP shortfall commitments3. Share Purchase Plan • The Placement will be offered at a price of A$0.015 per New Share (“Placement Offer Price”), which represents a: o 21.1% discount to the last close price of A$0.019 as of Tuesday, 21 July 2026; o 22.3% discount to the 5-day volume weighted average price (“VWAP”); and • The SPP offer price (“SPP Offer Price”) will be the lower of: o A$0.015 equal to the Placement Offer Price; or o A 2.5% discount to the VWAP of shares traded on the ASX during the five trading days up to the closing date of the SPP, rounded to the nearest 0.1 cent. Placement & SPP Offer Price • Participants in the Placement and SPP will receive one (1) free option (“Attaching Options”) for every one (1) New Share subscribed for under the Placement and SPP. Subject to satisfying spread requirements set out in ASX Listing Rule 2.5, condition 6, the Attaching Options are intended to be quoted on the ASX with an exercise price of A$0.018 (20% premium to the Offer Price) and an expiry date of 31 July 2029. • Attaching Options issued under the Placement are subject to shareholder approval at an EGM of the Company to be held on or around Friday, 11 September 2026 Attaching Options • Participants in the US Direct Registration Offering will subject to shareholder approval, receive one (1) warrant to purchase one (1) ADS (“ADR Warrant”) for every ADS subscribed for under the US Direct Registration Offering. • Each ADR will have an exercise price of US$3.79 per ADS, expiring 31 July 2029. The ADR will not be quoted on the ASX ADR Warrant • All new shares issued under the Placement and SPP will rank equally with existing RAD shares from the date of issue Ranking • Bell Potter Securities Limited (“Bell Potter”) are acting as Lead Manager and Bookrunner to the Placement & SPP Lead Manager • H.C. Wainwright & Co., LLC (“Wainwright”) US Placement Agent 1 Assumes a fully subscribed A$6m SPP 2The Company reserves the right to accept oversubscriptions under the SPP up to an additional A$4.0 million 3Investors providing SPP shortfall commitments will be issued an aggregate of 200,000,000 options on the same terms as the Attaching Options, subject to shareholder approval 23 USE OF FUNDS Capital raising proceeds will fund its commencement of the RAD101 registrational study while progressing multiple therapeutic programs through key clinical milestones and supporting ongoing strategic partnering initiatives A$M SOURCE OF FUNDS $10m Existing Cash Balance1 $18.5m Capital Raising2 $28.5m TOTAL 1As of 3 July 2026 2A$12.5 million Placement & and fully subscribed A$6.0 million SPP A$M CAPITAL RAISE USE OF FUNDS Drug Manufacturing $5.7m CMC GMP production for RAD 204 & RAD 202(new batches for Phase II); CMC GMP production for RAD 402; RV01 (new batches for Phase II) CMC GMP production for RAD 101 (new batches for Phase III) Clinical Trials $13.3m Phase 1 RAD 204, RAD 202, RV01, RAD 402 Phase 3 initiation for RAD 101 Administration, Working Capital and Offer Costs $9.5m General working capital, corporate costs, and offer costs $28.5m TOTAL 24 INDICATIVE TIMETABLE Key dates for the proposed offer - indicative only and subject to change Date (Sydney Time)2 Indicative capital raising timetable1 Wednesday, 22 July 2026 Trading Halt Wednesday, 22 July 2026 Placement Bookbuild Opens 7:00pm (AEST) Thursday, 23 July 2026 Record Date for SPP (7:00pm AEST) Friday, 24 July 2026 Capital raising announced, and trading halt lifted Friday, 31 July 2026 Settlement of Placement Shares Monday, 3 August 2026 Allotment of Placement Shares Friday, 7 August 2026 SPP Opens Thursday, 10 September 2026 SPP Closes Expected on or around Friday, 11 September 2026 EGM to approve New Shares under Tranche 2 of the Placement, SPP Offer and Attaching Options Expected on or around Tuesday, 15 September 2026 Announce results of SPP Expected on or around Wednesday, 16 September 2026 Settlement of New Shares issued under the Tranche 2 Placement, SPP Offer and Attaching Options Expected on or around Thursday, 17 September 2026 Allotment of New Shares issued under the Tranche 2 Placement, SPP Offer and Attaching Options 1 The timetable is indicative only and subject to change by the Company and Lead Manager, subject to the Corporations Act and other applicable laws 2 All times are expressed in Australian Eastern Standard Time (AEST) unless otherwise indicated 25 KEY RISKS Radiopharm’s ability to achieve profitability is dependent on a number of factors, including its ability to complete successful clinical trials, obtain regulatory approval for its products and successfully commercialise those products. There is no guarantee that Radiopharm’s products will be commercially successful. Pipeline product in development and not approved for commercial sale Radiopharm may be unable to secure necessary approvals from regulatory agencies and institutional bodies (clinics and hospitals) to conduct future clinical trials. There is also no assurance that products developed using Radiopharm’s technology will prove to be safe and efficacious in clinical trials, or that the regulatory approval to manufacture and market its products will be received. Clinical trials might also potentially expose Radiopharm to product liability claims in the event its products in development have unexpected effects on clinical subjects. Unsuccessful clinical trial results could have a significant impact on the value of Radiopharm’s securities and the future commercial development of its technologies. Clinical trial risk The research, development, manufacture, marketing and sale of products using Radiopharm’s technology are subject to varying degrees of regulation by a number of government authorities in Australia and overseas. Products may also be submitted for reimbursement approval. The availability and timing of that approval may have an impact upon the uptake and profitability of products in some jurisdictions. Regulatory and reimbursement approvals Radiopharm has not yet commercialised its technology and as yet has no material revenues. Commercialisation of products and potential market failure Radiopharm depends on the talent and experience of its personnel as its primary asset. There may be a negative impact on Radiopharm if any of its key personnel leave. Dependence upon key personnel 26 KEY RISKS (CONT.) Radiopharm may pursue collaborative arrangements with pharmaceutical and life science companies, academic institutions or other partners to complete the development and commercialisation of its products. There is no assurance that Radiopharm will attract and retain appropriate strategic partners or that any such collaborators will perform and meet commercialisation goals. If Radiopharm is unable to find a partner, it would be required to develop and commercialise potential products at its own expense. This may place significant demands on the Company’s internal resources and potentially delay the commercialisation of its products. Arrangements with third- party collaborators Radiopharm may experience delay in achieving a number of critical milestones, including securing commercial partners, completion of clinical trials, obtaining regulatory approvals, manufacturing, product launch and sales. Any material delays may impact adversely upon the Company, including the timing of any revenues under milestone or sales payments. Risk of delay and continuity of operations The biotechnolog